Use of Fenoldopam in Children with Congenital Heart Disease to Decrease Fluid Balance: A Retrospective, Descriptive Study and Insights into Predictors of Decreased Fluid Balance

Abstract

This retrospective study aimed to determine if fenoldopam is associated with a decrease in fluid balance and to define the factors that may promote this in children with a history of congenital heart disease at the cardiac intensive care unit (CICU). Patients cared from January 2014 to December 2018 in the CICU were reviewed, and those on fenoldopam infusion were identified. Patient cohort data included demographics, clinical information, laboratory results, hemodynamic and urine output measurements, and information regarding fenoldopam infusion were compared between those with and without decrease in fluid balance. Forty-six patients were identified. Patients received a starting dose of fenoldopam of 0.2 mcg/kg/h, a maximum dose of 0.3 mcg/kg/h, and duration of 64 hours. Over the 4-hour study period, statistically significant change was noted in systolic pressure (decrease of 5.4%; p < 0.001), diastolic pressure (decrease of 3.5%; p = 0.01), fluid balance, and urine output (decrease of 1.3%; p = 0.027). In the cohort, 34 patients (74%) had a decrease in fluid balance, 18 (39%) had an increase in urine output, and 25 (54%) had a decrease in fluid input after the initiation of fenoldopam. Patients that had a decrease in fluid balance tended to have a higher blood urea nitrogen level at the time of fenoldopam initiation. Fenoldopam was associated with decrease in fluid balance and fluid input, but not associated with an increase in urine output. The identification of factors that can decrease fluid balance may help identify those patients who can be benefited with this treatment.

Keywords

fenoldopam - pediatrics - critical care - fluid balance - nephrology - hemodynamics

Publication History

Received: 22 December 2020

Accepted: 18 January 2021

Article published online:
19 February 2021

• References

• 1 Kozik DJ, Tweddell JS. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2006; 81 (06) S2347-S2354
• 2 Costello JM, Thiagarajan RR, Dionne RE. et al. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Pediatr Crit Care Med 2006; 7 (01) 28-33
• 3 van der Vorst MM, Ruys-Dudok van Heel I, Kist-van Holthe JE. et al. Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery. Intensive Care Med 2001; 27 (04) 711-715
• 4 Thomas CA, Morris JL, Sinclair EA, Speicher RH, Ahmed SS, Rotta AT. Implementation of a diuretic stewardship program in a pediatric cardiovascular intensive care unit to reduce medication expenditures. Am J Health Syst Pharm 2015; 72 (12) 1047-1051
• 5 Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345 (21) 1548-1557
• 6 Mathur VS, Swan SK, Lambrecht LJ. et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27 (09) 1832-1837
• 7 Hegde SS, Lokhandwala MF. Renal dopamine and sodium excretion. Am J Hypertens 1990; 3 (6 Pt 2): 78S-81S
• 8 Gillies MA, Kakar V, Parker RJ, Honoré PM, Ostermann M. Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis. Crit Care 2015; 19: 449
• 9 Ricci Z, Stazi GV, Di Chiara L. et al. Fenoldopam in newborn patients undergoing cardiopulmonary bypass: controlled clinical trial. Interact Cardiovasc Thorac Surg 2008; 7 (06) 1049-1053
• 10 Ressia L, Calevo MG, Lerzo F, Carleo AM, Petrucci L, Montobbio G. Beneficial effect of fenoldopam mesylate in preventing peak blood lactate level during cardiopulmonary bypass for paediatric cardiac surgery. Interact Cardiovasc Thorac Surg 2014; 19 (02) 178-182
• 11 Ricci Z, Luciano R, Favia I. et al. High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. Crit Care 2011; 15 (03) R160
• 12 Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165 (06) 710-718